Biogen Idec - Database of Clinical Trials by Pharmaceutical Companies

All Categories Pharma Companies » Biogen Idec

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Condition: Healthy Volunteers
Interventions: Drug: Warfarin; Drug: Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012
Evaluation of Brain Atrophy in CIS Patients on Avonex

Condition: Multiple Sclerosis
Intervention:
Sponsors: University at Buffalo; University at Buffalo; Biogen Idec; Jacobs Neurological Institute; Department of Neurology and Center of Clinical Neuroscience and; Department of Radiology, Charles University in Prague, First Faculty; of Medicine, Prague, Czech Republic
Active, not recruiting - verified May 2012
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Natalizumab (Tysabri)
Sponsors: Cornerstone Health Care, PA; Cornerstone Health Care, PA; Biogen Idec
Recruiting - verified May 2012
A Study in Healthy Volunteers to Evaluate Effects of Pre-Medication or Slow Dose Titration on Flushing and Gastrointestinal Events

Condition: Healthy Volunteers
Interventions: Drug: Standard dose BG00012; Drug: Aspirin placebo; Drug: Aspirin; Drug: Escalating doses of BG00012; Drug: BG00012 placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Cimetidine plus Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Completed - verified May 2012
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Condition: Lymphoma
Interventions: Drug: Y Zevalin; Drug: In Zevalin; Drug: Rituxan; Drug: BCNU; Drug: VP -16; Drug: Ara-C; Drug: Melphalan; Procedure: Stem Cell Infusion; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Biogen Idec
Completed - verified February 2012
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Dexpramipexole; Drug: Dexpramipexole Placebo; Drug: Moxifloxacin
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified January 2012
Multiple Sclerosis and Progressive Resistance Training

Condition: Multiple Sclerosis (Relapsing Remitting)
Interventions: Behavioral: Training; Behavioral: Control
Sponsors: University of Aarhus; University of Aarhus; Sport Science, Institute of Public Health, Aarhus University; Department of Neurology, Aarhus University Hospital, NBG; MR-Research Centre, Aarhus University Hospital, Skejby; Department of Endocrinology, Aarhus University Hospital, NBG; Biogen Idec
Recruiting - verified February 2012
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Condition: Multiple Sclerosis
Interventions: Drug: Interferon beta-1a (current approved manufacturing process invloving FBS); Drug: Interferon beta-1a (new process, manufactured without FBS)
Sponsors: Biogen Idec; Biogen Idec
Completed - verified May 2012
Fampridine Pregnancy Exposure Registry

Conditions: Multiple Sclerosis; Pregnancy
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified February 2012
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Condition: Relapsing-remitting Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012
Canadian Avonex PEN Productivity Study

Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified March 2012
ATLAS - Anti-Tweak in Lupus Nephritis Patients

Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified May 2012
Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012
Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of rFVIIIFc in Paediatric Patients With Hemophilia A.

Condition: Hemophilia A
Intervention: Drug: rFVIIIFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum; Biogen Idec MA Inc.
Not yet recruiting - verified March 2012
MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia

Condition: Multiple Sclerosis
Interventions: Other: clinical and neurological evaluation; Other: Blood Sample; Genetic: Blood Sample
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers

Condition: Healthy
Interventions: Drug: BG00012 Dose 1; Drug: BG00012 Dose 2
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified March 2012
Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Condition: Hemophilia A
Intervention: Drug: rFVIIIFc
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified November 2011
Dexpramipexole SAD/MAD Study

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Dexpramipexole Placebo
Sponsors: Biogen Idec; Biogen Idec
Completed - verified January 2012
Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB 029, in Pediatric PTP Subjects With Hemophilia B.

Condition: Hemophilia B
Intervention: Drug: rFIXFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum
Recruiting - verified May 2012
Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Condition: Severe Hemophilia B
Intervention: Drug: rFIXFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum
Not yet recruiting - verified December 2011
Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

Condition: Healthy Volunteers
Intervention: Drug: Experimental
Sponsors: Biogen Idec; Biogen Idec
Completed - verified November 2011
An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™

Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012
Dexpramipexole Japanese PK Study

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Single dose reduced; Drug: Single dose standard; Drug: Multiple Dose; Drug: Multiple Dose
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012
Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

Condition: Sciatica
Interventions: Drug: BG00010; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified September 2011
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Elan Pharmaceuticals
Recruiting - verified March 2012
An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Daclizumab High Yield Process prefilled syringe
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified April 2012
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified December 2011
Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Condition: Healthy Volunteers
Interventions: Drug: BIIB023 - low dose IV Dose; Drug: BIIB023 - high dose IV Dose
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BIIB037; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified July 2011
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Condition: Healthy
Intervention: Drug: Avonex
Sponsors: Biogen Idec; Biogen Idec
Completed - verified November 2011
Dexpramipexole Renal PK Study

Conditions: Amyotrophic Lateral Sclerosis; Renal Insufficiency
Interventions: Drug: Dexpramipexole (dose 1); Drug: Dexpramipexole (dose 2)
Sponsors: Biogen Idec; Biogen Idec
Completed - verified January 2012
Avonex PEN Satisfaction and Patients Experience Clinical Trial

Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Active, not recruiting - verified March 2012